Global Polycystic Kidney Disease Drugs Market 2019-2023
Global Polycystic Kidney Disease Drugs Market: About this market
Polycystic kidney disease is a genetic disorder in which clusters of cysts develop primarily within the kidneys, causing kidneys to enlarge and lose function over time. Technavio’s polycystic kidney disease drugs market analysis considers the revenue generation from both autosomal dominant polycystic kidney disease (ADPKD), and autosomal recessive polycystic kidney disease (ARPKD). Our analysis also considers the sales of polycystic kidney disease drugs in North America, Europe, Asia, and ROW. In 2018, the ARPKD segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as the growing prevalence of the disease will play a significant role in the ARPKD segment to maintain its market position. Our global polycystic kidney disease drugs market report looks at factors such as the high prevalence of chronic kidney diseases, special regulatory designations, and the increasing R&D for developing new drugs. However, the lack of approved drugs, availability of substitute treatment options, and stringent regulations may hamper the growth of the polycystic kidney disease drugs industry over the forecast period.
Global polycystic kidney disease drugs market: Overview
Special regulatory designations
The growing focus on developing and evaluating drugs that effectively cure and diagnose rare diseases is encouraging organizations such as the US FDA and EMA to provide special regulatory designations to underlying companies. This provides companies with benefits such as tax credits for clinical trials and protocol assistance. These designations help vendors to easily launch drugs, which will help them in generating revenues. Thus, the special regulatory designations will fuel the growth of the polycystic kidney disease drugs market at a CAGR of more than 6% during the forecast period.
Favorable reimbursement policies
The high cost of off-label drugs and the approved novel drug for the treatment of polycystic kidney disease makes it challenging for patients to afford it. Hence, government and non-government organizations are introducing reimbursement policies to help patients in availing the treatment. These policies are further encouraging vendors to increase investments in R&D. Thus, the presence of favorable reimbursement policies will fuel the growth of the market.
For the detailed list of factors that will drive the global polycystic kidney disease drugs market during the forecast period 2019-2023, click here.
With the presence of several major players, the global polycystic kidney disease drugs market is moderately fragmented. Technavio’s robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading polycystic kidney disease drugs providers, that include Johnson & Johnson Services Inc., Merck & Co., Inc., Otsuka Holdings Co. Ltd., Reata Pharmaceuticals Inc., and Sanofi.
Also, the polycystic kidney disease drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook